Below are the Observational studies that the ACTU is currently involved in. Click on the links to learn more about each of these studies.
A short list of all the Observational studies on this page.
ACTG 5001 ALLRT stands for Adult AIDS Clinical Trials Group Longitudinal Linked Randomized Trials. It is a protocol designed to establish a group of patients who will be followed over approximately 5 years. ALLRT will study clinical outcomes as well as collect information about the immune system through laboratory tests, dosing information, quality of life measurements, and other measures. ALLRT is different from other protocols, because it follows you both on and between other ACTG studies, and ALLRT "pools" information across studies to answer its research questions. No medications are provided directly through this study.
- HIV positive and at least 13 years of age.
- Enrolled in an approved ACTG study or just finished with an approved ACTG study.
- Willing to be followed for at least 4 years.
- Willing to have additional blood drawn if your other study does not provide all the necessary samples or you are between studies.
- Willing to allow the ALLRT study team to access information from your other studies.
- Willing and able to come for study visits 3 times per year even when not on another study.
For more information contact Sara Powell at (513)584-6617.
Role of Regulatory T cells in HIV.
- HIV positive and at least 18 years of age.
- Willingness to undergo tonsillar biopsy.
- History of tonsillectomy
- Additional criteria varies depending on study group assignment.
For more information contact Eva Moore at (513)584-4819 or Sara Powell at (513)584-6617.
An International, Multicenter, Prospective Observational Study of the Safety of Maraviroc Used With Optimized Background Therapy in Treatment-Experienced HIV-1 Infected Patients. Note: after Trofile, this study is only an IDC chart review.
- Readable Trofile.
- Willing to provide alternate contact person for survival status. In case of death, next of kin may be approached.
- Recipient of a small molecule CCR5 inhibitor other than maraviroc.
For more information contact Aimee Samuels at (513)584-1490 or Sara Powell at (513)584-6617.